Non-alcoholic fatty liver disease and extra-hepatic cancers

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Sanna, Claudia ^a   Rosso, Chiara ^a   Marietti, Milena ^a   Bugianesi, Elisabetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adipokines; Colorectal cancer; Fatty liver; Gut microbiota

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROSTAGLANDIN E2; SOMATOMEDIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADENOMATOUS POLYP; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DYSBIOSIS; DYSPLASIA; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MELANOMA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; METASTASIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS CANCER; PREVALENCE; PROSTATE CANCER; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); GASTROINTESTINAL NEOPLASMS; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE;

GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL NEOPLASMS; HUMANS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84967278705     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050717     Document Type: Review

References (109)

1. Armstrong, M.J.; Houlihan, D.D.; Bentham, L.; Shaw, J.C.; Cramb, R.; Olliff, S.; Gill, P.S.; Neuberger, J.M.; Lilford, R.J.; Newsome, P.N. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 2012, 56, 234–240. [CrossRef] [PubMed]
2. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2015. [CrossRef] [PubMed]
3. Abd El-Kader, S.M.; El-Den Ashmawy, E.M.S. Non-alcoholic fatty liver disease: The diagnosis and management. World J. Hepatol. 2015, 7, 846–858. [CrossRef] [PubMed]
4. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011, 43, 617–649. [CrossRef] [PubMed]
5. Adams, L.A.; Lymp, J.F.; St Sauver, J.; Sanderson, S.O.; Lindor, K.D.; Feldstein, A.; Angulo, P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005, 129, 113–121. [CrossRef] [PubMed]
6. Ekstedt, M.; Franzén, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865–873. [CrossRef] [PubMed]
7. Rafiq, N.; Bai, C.; Fang, Y.; Srishord, M.; McCullough, A.; Gramlich, T.; Younossi, Z.M. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 2009, 7, 234–238. [CrossRef] [PubMed]
8. Angulo, P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 2010, 51, 373–375. [CrossRef] [PubMed]
9. Tilg, H.; Moschen, A.R. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract. Res. Clin. Gastroenterol. 2014, 28, 599–610. [CrossRef] [PubMed]
10. Tilg, H.; Diehl, A.M. NAFLD and extrahepatic cancers: Have a look at the colon. Gut 2011, 60, 745–746. [CrossRef] [PubMed]
11. Vanni, E.; Marengo, A.; Mezzabotta, L.; Bugianesi, E. Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander. Semin. Liver Dis. 2015, 35, 236–249. [CrossRef] [PubMed]
12. Bugianesi, E.; McCullough, A.J.; Marchesini, G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005, 42, 987–1000. [CrossRef] [PubMed]
13. Perseghin, G. Viewpoints on the way to a consensus session: Where does insulin resistance start? The liver. Diabetes Care 2009, 32, S164–S167. [CrossRef] [PubMed]
14. Scalera, A.; Tarantino, G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J. Gastroenterol. 2014, 20, 9217–9228. [PubMed]
15. Hwang, S.T.; Cho, Y.K.; Park, J.H.; Kim, H.J.; Park, D.I.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Won, K.H.; Jin, W. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J. Gastroenterol. Hepatol. 2010, 25, 562–567. [CrossRef] [PubMed]
16. Lee, Y.I.; Lim, Y.-S.; Park, H.S. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. J. Gastroenterol. Hepatol. 2012, 27, 91–95. [CrossRef] [PubMed]
17. Wong, V.W.-S.; Wong, G.L.-H.; Tsang, S.W.-C.; Fan, T.; Chu, W.C.; Woo, J.; Chan, A.W.; Choi, P.C.; Chim, A.M.; Lau, J.Y., et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011, 60, 829–836. [CrossRef] [PubMed]
18. Stadlmayr, A.; Aigner, E.; Steger, B.; Scharinger, L.; Lederer, D.; Mayr, A.; Strasser, M.; Brunner, E.; Heuberger, A.; Hohla, F., et al. Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia. J. Intern. Med. 2011, 270, 41–49.
19. Huang, K.-W.; Leu, H.-B.; Wang, Y.-J.; Luo, J.C.; Lin, H.C.; Lee, F.Y.; Chan, W.L.; Lin, J.K.; Chang, F.Y. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal. Dis. 2013, 15, 830–835. [CrossRef] [PubMed]
20. Sørensen, H.T.; Mellemkjaer, L.; Jepsen, P.; Thulstrup, A.M.; Baron, J.; Olsen, J.H.; Vilstrup, H. Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study. J. Clin. Gastroenterol. 2003, 36, 356–359.
21. Touzin, N.T.; Bush, K.N.V.; Williams, C.D.; Harrison, S.A. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Ther. Adv. Gastroenterol. 2011, 4, 169–176. [CrossRef]
22. Basyigit, S.; Uzman, M.; Kefeli, A.; Sapmaz, F.P.; Yeniova, A.O.; Nazligul, Y.; Asiltürk, Z. Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma. Int. J. Clin. Exp. Med. 2015, 8, 18601–18610. [PubMed]
23. Bhatt, B.D.; Lukose, T.; Siegel, A.B.; Brown, R.S.; Verna, E.C. Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J. Gastrointest. Oncol. 2015, 6, 459–468. [PubMed]
24. Wong, M.C.S.; Ching, J.Y.L.; Chan, V.C.W.; Lam, T.Y.; Luk, A.K.; Wong, S.H.; Ng, S.C.; Wong, V.W.; Ng, S.S.; Wu, J.C., et al. Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. Int. J. Cancer 2015. [CrossRef]
25. Lin, X.F.; Shi, K.Q.; You, J.; Liu, W.Y.; Luo, Y.W.; Wu, F.L.; Chen, Y.P.; Wong, D.K.; Yuen, M.F.; Zheng, M.H. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study. Mol. Biol. Rep. 2014, 41, 2989–2997. [PubMed]
26. Bilici, A.; Ozguroglu, M.; Mihmanlı, ˙I.; Turna, H.; Adaletli, ˙I. A case—Control study of non-alcoholic fatty liver disease in breast cancer. Med. Oncol. 2007, 24, 367–371. [CrossRef]
27. Vongsuvanh, R.; George, J.; Qiao, L.; van der Poorten, D. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 2013, 330, 1–10.
28. Moore, L.L.; Bradlee, M.L.; Singer, M.R.; Splansky, G.L.; Proctor, M.H.; Ellison, R.C.; Kreger, B.E. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 559–567.
29. Giovannucci, E.; Ascherio, A.; Rimm, E.B.; Colditz, G.A.; Stampfer, M.J.; Willett, W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med. 1995, 122, 327–334. [CrossRef] [PubMed]
30. Schoen, R.E.; Tangen, C.M.; Kuller, L.H.; Burke, G.L.; Cushman, M.; Tracy, R.P.; Dobs, A.; Savage, P.J. Increased blood glucose and insulin, body size, and incident colorectal cancer. J. Natl. Cancer Inst. 1999, 91, 1147–1154. [CrossRef] [PubMed]
31. Pischon, T.; Lahmann, P.H.; Boeing, H.; Friedenreich, C.; Norat, T.; Tjønneland, A.; Halkjaer, J.; Overvad, K.; Clavel-Chapelon, F.; Boutron-Ruault, M.C., et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2006, 98, 920–931. [CrossRef] [PubMed]
32. Beddy, P.; Howard, J.; McMahon, C.; Knox, M.; de Blacam, C.; Ravi, N.; Reynolds, J.V.; Keogan, M.T. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br. J. Surg. 2010, 97, 1028–1034. [CrossRef] [PubMed]
33. Corley, D.A.; Kubo, A.; Levin, T.R.; Block, G.; Habel, L.; Zhao, W.; Leighton, P.; Quesenberry, C.; Rumore, G.J.; Buffler, P.A. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology 2007, 133, 34–41. [CrossRef] [PubMed]
34. Edelstein, Z.R.; Farrow, D.C.; Bronner, M.P.; Rosen, S.N.; Vaughan, T.L. Central adiposity and risk of Barrett’s esophagus. Gastroenterology 2007, 133, 403–411. [CrossRef] [PubMed]
35. El-Serag, H.B.; Kvapil, P.; Hacken-Bitar, J.; Kramer, J.R. Abdominal obesity and the risk of Barrett’s esophagus. Am. J. Gastroenterol. 2005, 100, 2151–2156. [CrossRef] [PubMed]
36. Renehan, A.G.; Tyson, M.; Egger, M.; Heller, R.F.; Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371, 569–578. [CrossRef]
37. Singh, S.; Sharma, A.N.; Murad, M.H.; Buttar, N.S.; El-Serag, H.B.; Katzka, D.A.; Iyer, P.G. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013, 11, 1399–1412. [CrossRef] [PubMed]
38. Steffen, A.; Schulze, M.B.; Pischon, T.; Dietrich, T.; Molina, E.; Chirlaque, M.D.; Barricarte, A.; Amiano, P.; Quirós, J.R.; Tumino, R., et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2079–2089. [CrossRef] [PubMed]
39. Aune, D.; Greenwood, D.C.; Chan, D.S.; Vieira, R.; Vieira, A.R.; Navarro Rosenblatt, D.A.; Cade, J.E.; Burley, V.J.; Norat, T. Body mass index, abdominal fatness and pancreatic cancer risk: A systematic review and non-linear dose-response meta-analysis of prospective studies. Ann. Oncol. 2012, 23, 843–852. [CrossRef] [PubMed]
40. Rose, D.P.; Vona-Davis, L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2013, 40, 1–12. [CrossRef] [PubMed]
41. Schmid, D.; Ricci, C.; Behrens, G.; Leitzmann, M.F. Adiposity and risk of thyroid cancer: A systematic review and meta-analysis. Obes. Rev. 2015, 16, 1042–1054. [CrossRef] [PubMed]
42. McGrowder, D.A.; Jackson, L.A.; Crawford, T.V. Prostate cancer and metabolic syndrome: Is there a link? Asian Pac. J. Cancer Prev. 2012, 13, 1–13. [CrossRef] [PubMed]
43. Merry, A.; Schouten, L.; Goldbohm, R.; van Den Brandt, P. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardias: A prospective cohort study. Gut 2007, 56, 1503–1511. [CrossRef] [PubMed]
44. El-Serag, H.; Ergun, G.; Pandolfino, J.; Fitzgerald, S.; Tran, T.; Kramer, J. Obesity increases oesophageal acid exposure. Gut 2007, 56, 749–755. [CrossRef] [PubMed]
45. Kubo, A.; Cook, M.; Shaheen, N.; Vaughan, T.; Whiteman, D.; Murray, L.; Corley, D.A. Sexspecific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: A pooled analysis from the international BEACON consortium. Gut 2013, 62, 1684–1691. [CrossRef] [PubMed]
46. El-Serag, H.; Hashmi, A.; Garcia, J.; Richardson, P.; Alsarraj, A.; Fitzgerald, S.; Vela, M.; Shaib, Y.; Abraham, N.S.; Velez, M., et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: A case-control study. Gut 2014, 63, 220–229. [CrossRef] [PubMed]
47. Garcia, J.; Splenser, A.; Kramer, J.; Alsarraj, A.; Fitzgerald, S.; Ramsey, D.; El-Serag, H.B. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett’s esophagus: A case-control study. Clin. Gastroenterol. Hepatol. 2014, 12, 229–238. [CrossRef] [PubMed]
48. Uzel, M.; Sahiner, Z.; Filik, L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: Single center experience. J. BUON 2015, 20, 662. [PubMed]
49. Esposito, K.; Chiodini, P.; Colao, A.; Lenzi, A.; Giugliano, D. Metabolic syndrome and risk of cancer. Diabetes Care 2012, 35, 2402–2411. [CrossRef] [PubMed]
50. Ljungberg, B.; Bensalah, K.; Canfield, S.; Dabestani, S.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; Lam, T.; Marconi, L.; Merseburger, A.S., et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 2015, 67, 913–924. [CrossRef] [PubMed]
51. Escudier, B.; Porta, C.; Schmidinger, M.; Algaba, F.; Patard, J.J.; Khoo, V.; Eisen, T.; Horwich, A. Renal cell carcinoma: ESMO clinical practice guidelines. Ann. Oncol. 2014, 25, iii49–iii56. [CrossRef] [PubMed]
52. Stocks, T.; Bjørge, T.; Ulmer, H.; Manjer, J.; Häggström, C.; Nagel, G.; Engeland, A.; Johansen, D.; Hallmans, G.; Selmer, R., et al. Metabolic risk score and cancer risk: Pooled analysis of seven cohorts. Int. J. Epidemiol. 2015, 44, 1353–1363. [CrossRef] [PubMed]
53. Zhu, Y.; Wang, H.K.; Zhang, H.L.; Yao, X.D.; Zhang, S.L.; Dai, B.; Shen, Y.J.; Liu, X.H.; Zhou, L.P.; Ye, D.W. Visceral obesity and risk of high grade disease in clinical T1A renal cell carcinoma. J. Urol. 2013, 189, 447–453. [CrossRef] [PubMed]
54. Horiguchi, A.; Ito, K.; Sumitomo, M.; Kimura, F.; Asano, T.; Hayakawa, M. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 2008, 38, 106–111. [CrossRef] [PubMed]
55. Lawlor, D.A.; Smith, G.D.; Ebrahim, S. Hyperinsulinaemia and increased risk of breast cancer: Findings from the British Women’s Heart and Health Study. Cancer Causes Control 2004, 15, 267–275. [CrossRef] [PubMed]
56. Rosato, V.; Bosetti, C.; Talamini, R.; Levi, F.; Montella, M.; Giacosa, A.; Negri, E.; La Vecchia, C. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. 2011, 22, 2687–2692. [CrossRef] [PubMed]
57. Agnoli, C.; Berrino, F.; Abagnato, C.A.; Muti, P.; Panico, S.; Crosignani, P.; Krogh, V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr. Metab. Cardiovasc. Dis. 2010, 20, 41–48. [CrossRef] [PubMed]
58. Berrino, F.; Villarini, A.; Traina, A.; Bonanni, B.; Panico, S.; Mano, M.P.; Mercandino, A.; Galasso, R.; Barbero, M.; Simeoni, M., et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res. Treat. 2014, 147, 159–165. [CrossRef] [PubMed]
59. MacInnis, R.J.; English, D.R. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control 2006, 17, 989–1003. [CrossRef] [PubMed]
60. Choi, W.M.; Lee, J.H.; Yoon, J.H.; Kwak, C.; Lee, Y.J.; Cho, Y.Y.; Lee, Y.B.; Yu, S.J.; Kim, Y.J.; Kim, H.H., et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr. Relat. Cancer 2014, 21, 343–353. [CrossRef] [PubMed]
61. Arase, Y.; Kobayashi, M.; Suzuki, F.; Suzuki, Y.; Kawamura, Y.; Akuta, N.; Imai, N.; Kobayashi, M.; Sezaki, H.; Matsumoto, N., et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol. Res. 2012, 42, 264–272. [CrossRef] [PubMed]
62. Wigg, A.J.; Roberts-Thomson, I.C.; Dymock, R.B.; McCarthy, P.J.; Grose, R.H.; Cummins, A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48, 206–211. [CrossRef] [PubMed]
63. Ohtani, N.; Yoshimoto, S.; Hara, E. Obesity and cancer: A gut microbial connection. Cancer Res. 2014, 74, 1885–1889. [CrossRef] [PubMed]
64. Lee, Y.Y. What is obesity doing to your gut? Malays. J. Med. Sci. 2015, 22, 1–3. [PubMed]
65. Moran, C.P.; Shanahan, F. Gut microbiota and obesity: Role in aetiology and potential therapeutic target. Best Pract. Res. Clin. Gastroenterol. 2014, 28, 585–597. [CrossRef] [PubMed]
66. Mehal, W.Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 637–644. [CrossRef] [PubMed]
67. Louis, P.; Hold, G.L.; Flint, H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014, 12, 661–672. [CrossRef] [PubMed]
68. Spruss, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, S.C.; Bergheim, I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50, 1094–1104. [CrossRef] [PubMed]
69. Gilbert, C.A.; Slingerland, J.M. Cytokines, obesity, and cancer: New insights on mechanisms linking obesity to cancer risk and progression. Annu. Rev. Med. 2013, 64, 45–57. [CrossRef] [PubMed]
70. Hui, J.M.; Hodge, A.; Farrell, G.C.; Kench, J.G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004, 40, 46–54. [CrossRef] [PubMed]
71. Giovannucci, E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res. 2003, 35, 694–704. [PubMed]
72. Pérez-Hernández, A.I.; Catalán, V.; Gómez-Ambrosi, J.; Rodríguez, A.; Frühbeck, G. Mechanisms linking excess adiposity and carcinogenesis promotion. Front. Endocrinol. 2014, 5, 65. [CrossRef]
73. Van Kruijsdijk, R.C.M.; van derWall, E.; Visseren, F.L.J. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2569–2578. [CrossRef] [PubMed]
74. Grimberg, A.; Cohen, P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 2000, 183, 1–9. [CrossRef]
75. Chan, J.M.; Stampfer, M.J.; Giovannucci, E.; Gann, P.H.; Ma, J.; Wilkinson, P.; Hennekens, C.H.; Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998, 279, 563–566. [CrossRef] [PubMed]
76. Giovannucci, E.; Pollak, M.N.; Platz, E.A.; Willett, W.C.; Stampfer, M.J.; Majeed, N.; Colditz, G.A.; Speizer, F.E.; Hankinson, S.E. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomark. Prev. 2000, 9, 345–349.
77. Yu, H.; Spitz, M.R.; Mistry, J.; Gu, J.; Hong, W.K.; Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J. Natl. Cancer Inst. 1999, 91, 151–156. [CrossRef] [PubMed]
78. Hankinson, S.E.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Michaud, D.S.; Deroo, B.; Rosner, B.; Speizer, F.E.; Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351, 1393–1396. [CrossRef]
79. Donohoe, C.L.; O’Farrell, N.J.; Doyle, S.L.; Reynolds, J.V. The role of obesity in gastrointestinal cancer: Evidence and opinion. Ther. Adv. Gastroenterol. 2014, 7, 38–50. [CrossRef] [PubMed]
80. Doyle, S.L.; Donohoe, C.L.; Finn, S.P.; Howard, J.M.; Lithander, F.E.; Reynolds, J.V.; Pidgeon, G.P.; Lysaght, J. IGF-1 and its receptor in esophageal cancer: Association with adenocarcinoma and visceral obesity. Am. J. Gastroenterol. 2012, 107, 196–204. [CrossRef] [PubMed]
81. Siahpush, S.H.; Vaughan, T.L.; Lampe, J.N.; Freeman, R.; Lewis, S.; Odze, R.D.; Blount, P.L.; Ayub, K.; Rabinovitch, P.S.; Reid, B.J., et al. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: Risk of neoplastic progression in Barrett’s esophagus. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2387–2395. [CrossRef] [PubMed]
82. Endo, H.; Hosono, K.; Uchiyama, T.; Sakai, E.; Sugiyama, M.; Takahashi, H.; Nakajima, N.; Wada, K.; Takeda, K.; Nakagama, H., et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60, 1363–1371. [CrossRef] [PubMed]
83. Jaffe, T.; Schwartz, B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int. J. Cancer 2008, 123, 2543–2556. [CrossRef] [PubMed]
84. Ho, G.Y.F.; Wang, T.; Gunter, M.J.; Strickler, H.D.; Cushman, M.; Kaplan, R.C.; Wassertheil-Smoller, S.; Xue, X.; Rajpathak, S.N.; Chlebowski, R.T., et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res. 2012, 72, 3029–3037. [CrossRef] [PubMed]
85. Rubenstein, J.H.; Dahlkemper, A.; Kao, J.Y.; Zhang, M.; Morgenstern, H.; McMahon, L.; Inadomi, J.M. A pilot study of the association of low plasma adiponectin and Barrett’s esophagus. Am. J. Gastroenterol. 2008, 103, 1358–1364. [CrossRef] [PubMed]
86. Rubenstein, J.H.; Morgenstern, H.; McConell, D.; Scheiman, J.M.; Schoenfeld, P.; Appelman, H.; McMahon, L.F., Jr.; Kao, J.Y.; Metko, V.; Zhang, M., et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology 2013, 145, 1237–1244. [CrossRef] [PubMed]
87. Ryan, A.M.; Healy, L.A.; Power, D.G.; Byrne, M.; Murphy, S.; Byrne, P.J.; Kelleher, D.; Reynolds, J.V. Barrett esophagus: Prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann. Surg. 2008, 247, 909–915. [CrossRef] [PubMed]
88. Chandar, A.K.; Devanna, S.; Lu, C.; Singh, S.; Greer, K.; Chak, A.; Iyer, P.G. Association of serum levels of adipokines and insulin with risk of barrett’s esophagus: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2015, 13, 2241–2255. [CrossRef] [PubMed]
89. Francois, F.; Roper, J.; Goodman, A.J.; Pei, Z.; Ghumman, M.; Mourad, M.; de Perez, A.Z.; Perez-Perez, G.I.; Tseng, C.; Blaser, M.J. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008, 57, 16–24. [CrossRef] [PubMed]
90. Kendall, B.J.; Macdonald, G.A.; Hayward, N.K.; Prins, J.B.; Brown, I.; Walker, N.; Pandeya, N.; Green, A.C.; Webb, P.M.; Whiteman, D.C., et al. Leptin and the risk of Barrett’s oesophagus. Gut 2008, 57, 448–454. [CrossRef] [PubMed]
91. Delort, L.; Rossary, A.; Farges, M.-C.; Vasson, M.-P.; Caldefie-Chézet, F. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci. 2015, 140, 37–48. [CrossRef] [PubMed]
92. Macciò, A.; Madeddu, C.; Mantovani, G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: New therapeutic perspectives. Obes. Rev. 2009, 10, 660–670. [CrossRef] [PubMed]
93. Caldefie-Chézet, F.; Dubois, V.; Delort, L.; Rossary, A.; Vasson, M.-P. Leptin: Involvement in the pathophysiology of breast cancer. Ann. Endocrinol. 2013, 74, 90–101. [CrossRef] [PubMed]
94. Filková, M.; Haluzík, M.; Gay, S.; Senolt, L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin. Immunol. 2009, 133, 157–170. [CrossRef] [PubMed]
95. Karapanagiotou, E.M.; Tsochatzis, E.A.; Dilana, K.D.; Tourkantonis, I.; Gratsias, I.; Syrigos, K.N. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008, 61, 391–397. [CrossRef] [PubMed]
96. Tiaka, E.K.; Manolakis, A.C.; Kapsoritakis, A.N.; Potamianos, S.P. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev. 2011, 22, 109–119. [CrossRef] [PubMed]
97. Codoñer-Franch, P.; Alonso-Iglesias, E. Resistin: Insulin resistance to malignancy. Clin. Chim. Acta 2015, 438, 46–54. [CrossRef] [PubMed]
98. Hursting, S.D.; Dunlap, S.M. Obesity, metabolic dysregulation, and cancer: A growing concern and an inflammatory (and microenvironmental) issue. Ann. N. Y. Acad. Sci. 2012, 1271, 82–87. [CrossRef] [PubMed]
99. Yadav, A.; Kumar, B.; Datta, J.; Teknos, T.N.; Kumar, P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res. 2011, 9, 1658–1667. [CrossRef] [PubMed]
100. Naylor, M.S.; Stamp, G.W.; Foulkes, W.D.; Eccles, D.; Balkwill, F.R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Investig. 1993, 91, 2194–2206. [CrossRef] [PubMed]
101. Ferrajoli, A.; Keating, M.J.; Manshouri, T.; Giles, F.J.; Dey, A.; Estrov, Z.; Koller, C.A.; Kurzrock, R.; Thomas, D.A.; Faderl, S., et al. The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood 2002, 100, 1215–1219. [PubMed]
102. Pikarsky, E.; Porat, R.M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431, 461–466. [CrossRef] [PubMed]
103. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9, 361–371. [CrossRef] [PubMed]
104. Liu, Z.; Brooks, R.S.; Ciappio, E.D.; Kim, S.J.; Crott, J.W.; Bennett, G.; Greenberg, A.S.; Mason, J.B. Diet-induced obesity elevates colonic TNF-α in mice and is accompanied by an activation of Wnt signaling: A mechanism for obesity-associated colorectal cancer. J. Nutr. Biochem. 2012, 23, 1207–1213. [CrossRef] [PubMed]
105. Angelo, L.S.; Talpaz, M.; Kurzrock, R. Autocrine interleukin-6 production in renal cell carcinoma: Evidence for the involvement of p53. Cancer Res. 2002, 62, 932–940. [PubMed]
106. Kai, H.; Kitadai, Y.; Kodama, M.; Cho, S.; Kuroda, T.; Ito, M.; Tanaka, S.; Ohmoto, Y.; Chayama, K. Involvement of proinflammatory cytokines IL-1β and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005, 25, 709–713. [PubMed]
107. Sethi, G.; Shanmugam, M.K.; Ramachandran, L.; Kumar, A.P.; Tergaonkar, V. Multifaceted link between cancer and inflammation. Biosci. Rep. 2012, 32, 1–15. [CrossRef] [PubMed]
108. Chung, Y.-C.; Chang, Y.-F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 2003, 83, 222–226. [CrossRef] [PubMed]
109. Lin, W.-W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Investig. 2007, 117, 1175–1183. [CrossRef] [PubMed]